Immunoglobulin (Ig)A-nephropathy (IgAN), the most common glomerulonephritis worldwide, is immunohistochemically characterized by the deposition of IgA in the renal mesangium. The mechanism of binding and deposition of IgA in the kidney is still not clear. It has been demonstrated that IgA-binding to mesangial cells (MCs) is followed by cell activation, as indicated by the enhanced expression of proinflammatory cytokines, the nuclear transcriptional factor (NF)kB, or the protooncogene c-jun. The binding of IgA to MC is mediated via the Fc part of the immunoglobulin, as demonstrated by blocking experiments using Fc-fragments of IgA. The known myeloid Fc receptor for IgA (FcαRI/CD89), as well as other known receptors able to bind IgA (asialoglycoprotein receptor, mannose receptor, secretory component), are not expressed on MC. However the hepatic asialoglycoprotein receptor, as well as the myeloid FcαRI, play an important role in the clearance of IgA from the circulation. In patients with IgAN, this function seems to be impaired, possibly as a consequence of reduced glycosylation of the hinge region of IgA1 which affects IgA-receptor interactions. This could lead to increased plasma levels of IgA, resulting in increased binding of IgA to MC via a hitherto unidentified Fc receptor for IgA. Recently, the expression of mRNA transcripts with partial identity to CD89 was reported on human MC in vitro. These transcripts could be part of this new receptor, with partial homology to recently discovered genes that map to chromosome 19Q13.4 and encode a family of type I transmembrane proteins.